-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Maintains Outperform on Amgen, Raises Price Target to $450

Benzinga·08/05/2026 11:56:05
语音播报
BMO Capital analyst Evan David Seigerman maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $400 to $450.